Schonfeld Strategic Advisors’s Biotech Acquisition Company Warrant BIOTW Stock Holding History
Bought
Maintained
Sold
Schonfeld Strategic Advisors's BIOTW Position: Q1 2023 in Review
Schonfeld Strategic Advisors sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 30,000 shares — an estimated $1.92K sold.
Schonfeld Strategic Advisors first reported a position in BIOTW in Q2 2022 and held it in 3 quarters. The position peaked at $3K in Q2 2022. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.
- Schonfeld Strategic Advisors reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
- Schonfeld Strategic Advisors sold 30,000 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $1.92K.
- Schonfeld Strategic Advisors first reported a position in Biotech Acquisition Company Warrant in Q2 2022 and held it in 3 quarters.
- Schonfeld Strategic Advisors's Biotech Acquisition Company Warrant position peaked at $3K in Q2 2022.
- 0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.
Based on Schonfeld Strategic Advisors's 13F filing for Q1 2023, filed 15 May 2023.